PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Should Baseline Characteristics Affect Choice of Treatment?

Susan B. Bressler,Wesley T. Beaulieu,Adam R. Glassman,Jeffrey G. Gross,Michele Melia,Eric Chen,Michael R. Pavlica,Lee M. Jampol

PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Should Baseline Characteristics Affect Choice of Treatment?

2019

Susan B. Bressler
Wesley T. Beaulieu
Adam R. Glassman
Jeffrey G. Gross
Michele Melia
Eric Chen
Michael R. Pavlica
Lee M. Jampol

Purpose:Among eyes with proliferative diabetic retinopathy, identify whether baseline characteristics impact the benefit of ranibizumab over panretinal photocoagulation (PRP) in DRCR.net Protocol S.Methods:Participants had proliferative diabetic retinopathy, visual acuity of 20/320 or better, and no

Keywords:

Ophthalmology
Surgery
Diabetic retinopathy
Ranibizumab
Diabetes mellitus
Medicine
Panretinal photocoagulation
Visual acuity
baseline characteristics

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations